Anemia

As Akebia Therapeutics announced plans to launch its anemia drug Vafseo to the dialysis community, company officials said they intend to work with the FDA for more testing of the drug for the pre-dialysis market.

Belzutifan significantly improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma, according to results of a randomized phase 3 trial.

A higher intake of heme iron may be linked to an increased risk for developing type 2 diabetes, study results published in Nature Metabolism showed.

More than half of people with iron deficiency continued to have low iron levels 3 years after diagnosis, according to retrospective study results.

LONG BEACH, Calif. — Hydralazine-induced autoimmune conditions may have a varied presentation, including drug-induced lupus or vasculitis, according to a speaker, here.

LONG BEACH, Calif. — Clinicians do not consistently use algorithms for dosing methoxy polyethylene glycol-epoetin beta when treating patients with anemia, presented research shows.

LONG BEACH, Calif. — Researchers reported results from a phase 1b/2a placebo-controlled study of DISC-0974, an anti-hemojuvelin antibody to treat anemia in patients with chronic kidney disease.

Akebia Therapeutics Inc. has received FDA approval for its oral anemia drug Vafseo for treating anemia in adults with end-stage kidney disease on dialysis for at least 3 months.

Anorexia nervosa during pregnancy was associated with several adverse neonatal outcomes, such as preterm and small for gestational age birth, compared with women without eating disorders, researchers reported.